LSBMD

(redirected from Lumbar Spine Bone Mineral Density)
AcronymDefinition
LSBMDLumbar Spine Bone Mineral Density
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Major Finding: Compared with RA patients without a cardiovascular disease event, those with at least one documented event had significantly lower total hip and lumbar spine bone mineral density, and were four times as likely to have osteoporosis (60% vs.
All of the study assessments were conducted at the beginning and end of the 36-week training period lumbar spine bone mineral density was assessed by DEXA scans (Lunar Prodigy Pro[TM]) at the local hospital.
RELATED ARTICLE: Major Finding: Lumbar spine bone mineral density at 12 months increased by 3.5% for the 1-mg zoledronate group, 44C 4% for the 2.5-mg group, and 3.6% for the standard 5-mg dose group (P less than .001 for each dose).
Lumbar spine bone mineral density (BMD) increased by 5.5% at 12 months and by 7.6% at 24 months in the denosumab group vs.
Major Finding: Lumbar spine bone mineral density at 12 months increased by 3.5% for the 1-mg zoledronate group, 4% for the 2.5-mg group, and 3.6% for the standard 5-mg dose group (P less than .001 for each dose).
SAN FRANCISCO -- Osteoporotic women treated with teriparatide often gain lumbar spine bone mineral density and lower their risk of vertebral fracture, even if they lose hip bone mineral density.
By the time adjuvant therapy ended after 3 years, they averaged a 14% reduction from baseline in lumbar spine bone mineral density (BMD).
"In patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate for 18 months, teriparatide resuited in significantly greater increases in lumbar spine bone mineral density (BMD) compared with alendronate.
On the primary end point, the mean percent change from baseline in the lumbar spine bone mineral density (BMD), a statistically significant difference of 4.53% was seen between the risedronate and placebo groups.
On the primary end point, mean percent change from baseline in the lumbar spine bone mineral density (BMD), a statistically significant difference of 4.53% was seen between the risedronate and placebo groups.
In a per-protocol analysis, mean lumbar spine bone mineral density scores increased 4% from baseline in the daily group and 5% in the monthly group after 1 year, and 5% and 7%, respectively, after 2 years.
Evaluation of the primary end point--the percentage change in lumbar spine bone mineral density from baseline to 12 months--indicated that denosumab was active and significantly superior to placebo (N.